Phaseline

Targets › PARP1

PARP1 (Poly [ADP-ribose] polymerase 1): drug programs, companies and trials

57 programs from 49 companies in 371 trials: 168 Phase 2, 150 Phase 1, 46 Phase 3, 7 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.

Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair. Mediates glutamate, aspartate, serine, threonine, histidine or tyrosine ADP-ribosylation of proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety,…. (UniProt, P09874)

Open in Phaseline: the race on PARP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaOlaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 4Metastatic Castration-resistant Prostate Cancer; Advanced Ovarian Cancer; Platinum Sensitive; Endometrial Neoplasms …Nov 2026
M.D. Anderson Cancer Center[18F]-4FN
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274Phase 4Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm …Dec 2026
GSKNiraparib
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 3Neoplasms, Breast; Ovarian Neoplasms; NeoplasmsDec 2026
Guangdong Provincial People's HospitalFuzuloparib
PARP inhibitor
PARP1, PARP2Phase 3Triple-negative Breast CancerDec 2026
Jiangsu HengRui MedicineFuzuloparib
PARP inhibitor
PARP1, PARP2Phase 3Metastatic Castration-Resistant Prostate Cancer (mCRPC)Dec 2026
Johnson & Johnson (Janssen)Niraparib
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 3Prostatic Neoplasms; Castration-Resistant Prostatic Cancer; Prostatic Neoplasms, Castration-Resistant; Ovarian Cancer …Dec 2026
PfizerTalazoparib
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 3Advanced Malignancies; mCRPC; Prostate Cancer; Urothelial Carcinoma …Dec 2026
BeiGenePamiparib (BGB-290)
Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor
PARP1, PARP2Phase 3Ovarian Cancer; Locally Advanced Prostate Cancer; Head and Neck Cancer; GlioblastomaJan 2027
Alliance for Clinical Trials in OncologyRucaparib camsylate
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 3Castration-Resistant Prostate CarcinomaMar 2027
Fudan UniversityFluzoparib
PARP inhibitor
PARP1, PARP2Phase 3Neoadjuvant Therapy; Breast Cancer; Breast Cancer MetastaticApr 2027
The Netherlands Cancer InstituteddAC-CP-Olaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP2, PARP3Phase 3Breast Cancer; Cancer; Ovarian CancerMay 2027
Merck & Co. (MSD)Olaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 3Lung Neoplasms; Small Cell Lung Cancer; Solid Tumors; Advanced Solid Neoplasms …May 2027
AstraZenecaSaruparib
PARP inhibitor
PARP1, PARP2Phase 3Metastatic Castration-Sensitive Prostate Cancer; Advanced Breast Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer …Sep 2027
TesaroNiraparib
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 3Ovarian NeoplasmsApr 2029
Tongji HospitalFluzoparib
PARP inhibitor
PARP1, PARP2Phase 3Ovarian CancerMay 2030
pharmaandRucaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 3Epithelial Ovarian Cancer; Leiomyosarcoma; Peritoneal Cancer; Adenocarcinoma of the Oesophagus …Dec 2030
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFluorizoparib
PARP1/2 inhibitor
PARP1, PARP2Phase 3Metastatic Breast CancerMar 2031
Impact TherapeuticsIMP4297
PARP inhibitor
PARP1, PARP2Phase 3Ovarian Cancer–
National Cancer Institute (NCI)Veliparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 2Acute Myeloid Leukemia; Glioblastoma; Locally Advanced Pancreatic Adenocarcinoma; Recurrent Lung Small Cell Carcinoma …Nov 2026
Ruijin HospitalFluzoparib
PARP inhibitor
PARP1, PARP2Phase 2SarcomaDec 2026
M.D. Anderson Cancer CenterTalazoparib Tosylate
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 2Prostate Cancer; Advanced Malignant Neoplasm; Malignant Female Reproductive System Neoplasm; Advanced Malignant Solid NeoplasmDec 2026
Memorial Sloan Kettering Cancer CenterTemozolomide
PARP inhibitor
PARP1Phase 2Glioma; Newly Diagnosed Ewing SarcomaJan 2027
Allarity Therapeutics2X-121
Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Tankyrase 1/2 inhibitor
PARP1, PARP2, TNKS2, TNKSPhase 2Advanced Ovarian CancerMar 2027
VIVUSVI-0609
Alkylating agent; nitrosourea
PARP1Phase 2LymphomaMar 2027
Sun Yat-sen UniversityTemozolomide
PARP inhibitor
PARP1, PARP2Phase 2Ewing SarcomaApr 2027
Peking University People's HospitalFluzoparib
PARP inhibitor
PARP1Phase 2Germline BRCA-mutated HER2-negative Breast CancerApr 2027
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSenaparib
PARP inhibitor
PARP1Phase 2Ovary CancerOct 2027
Tianjin Medical University Cancer Institute and HospitalFluzoparib
Poly (ADP-ribose) polymerase (PARP) inhibitor
PARP1, PARP2Phase 2Platinum-sensitiveNov 2027
Yonsei UniversityNesuparib
PARP inhibitor
PARP1Phase 2Endometrial CancerDec 2027
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNicotinamide (NAM)
NAD+ precursor; promotes NAD+ biosynthesis and may support cellular metabolism and anti-in
PARP1, NAD1, NAMPTPhase 2Fatty LiverDec 2027
Fujian Cancer HospitalFuzuloparib
PARP inhibitor
PARP1, PARP2Phase 2Ovarian NeoplasmsDec 2027
AstraZenecaAZD5305
PARP inhibitor
PARP1, PARP2Phase 1Prostate Cancer; Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer; Ovarian Cancer; Breast Cancer …Nov 2026
Chia Tai Tianqing Pharmaceutical GroupTQB3122 Capsules
PARP1 inhibitor
PARP1Phase 1Advanced CancerDec 2026
Hangzhou SynRx Therapeutics Biomedical TechnologySYN818
PARP inhibitor
PARP1Phase 1Advanced Solid Cancer; Metastatic Solid TumorDec 2026
Jun GuoFluzoparib
PARP inhibitor
PARP1, PARP2Phase 1MelanomaDec 2026
DIGMBIODM5167
PARP-1 inhibitor
PARP1Phase 1Advanced Breast CancerJan 2027
Daewoong PharmaceuticalOlaparib (DWZ2501)
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 1CancerMar 2027
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNiraparib Tosylate Monohydrate
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 1Ovarian CancerMar 2027
Eikon TherapeuticsIMP1734
PARP1 selective inhibitor
PARP1Phase 1Advanced Solid TumorJun 2027
Memorial Sloan Kettering Cancer CenterPARPi-FL
PARP inhibitor-based fluorescent imaging dye
PARP1, PARP2Phase 1Oral Squamous Cell Carcinoma (OSCC)Jul 2027
Abramson Cancer Center at Penn Medicine[18F]FluorThanatrace
PARP-1 targeted PET imaging agent
PARP1Phase 1Breast Cancer; Neuroendocrine Carcinoma Metastatic; Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerJul 2027
Memorial Sloan Kettering Cancer Center[18F]-PARPi
PARP inhibitor-based PET imaging agent
PARP1, PARP2Phase 1Head and Neck CancerAug 2027
AstraZenecaPalacaparib (AZD9574)
PARP inhibitor
PARP1, PARP2Phase 1Breast Cancer; Advanced Solid Malignancies; Metastatic Prostate CancerSep 2027
University of WashingtonFluorine F 18 Fluorthanatrace
PARP1-targeted radiotracer for PET imaging
PARP1Phase 1Anatomic Stage IV Breast Cancer AJCC v8Dec 2027
Shanghai SciBrunch TherapeuticsSPR1020
PARP1 inhibitor
PARP1Phase 1Advanced Solid TumorsFeb 2028
Nerviano Medical Sciencesatamparib
PARP inhibitor
PARP1Phase 1NSCLC AdenocarcinomaJul 2028
Duke Street BioDSB2455
PARP1 selective inhibitor
PARP1Phase 1Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)Aug 2028
Eikon TherapeuticsEIK1004 (IMP1707)
PARP1 selective inhibitor
PARP1Phase 1Advanced Solid TumorsDec 2028
Acerand Therapeutics (Shanghai)ACE-86225106
PARP inhibitor
PARP1, PARP2Phase 1Solid Tumor, AdultDec 2028
Haisco Pharmaceutical GroupHSK46256
PARP1 inhibitor
PARP1Phase 1Advanced Solid Tumor (Phase 1)Dec 2028
Fundación de investigación HM177Lu-DOTATATE (Lutathera®)
PARP inhibitor
PARP1Phase 1Solid Tumor CancerJul 2029
VA Office of Research and DevelopmentStenoparib/Temozolomide
PARP inhibitor plus alkylating agent
PARP1, PARP2Phase 1Relapsed Small Cell Lung CancerDec 2029
AstraZenecaAZD4956
PARP inhibitor
PARP1, PARP2Phase 1Solid TumoursMar 2030
Xing XieFuzuloparib
PARP inhibitor
PARP1, PARP2Phase 1Efficacy and Safety–
Jiangsu Hansoh PharmaceuticalHS-10502
PARP1-specific selective inhibitor
PARP1Phase 1Ovarian Cancer; Recurrent Ovarian Cancer–
Boryung PharmaceuticalOlaparib (BR2022)
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 1Ovarian Cancer–
Zhejiang Yangli Pharmaceutical TechnologyVB15010
PARP1 inhibitor
PARP1Phase 1Cancer–

Conditions

Ovarian Cancer (26) Breast Cancer (18) Prostate Cancer (12) Advanced Malignant Solid Neoplasm (10) Acute Myeloid Leukemia (9) Endometrial Cancer (5) Advanced Breast Cancer (5) Glioblastoma (5) Metastatic Prostate Cancer (5) Metastatic Breast Cancer (4) Metastatic Castration-resistant Prostate Cancer (4) Glioma (4)

Modalities

small molecule (43), mixed (10), antibody (4)

Companies

AstraZeneca (5) Memorial Sloan Kettering Cancer Center (3) Eikon Therapeutics (2) M.D. Anderson Cancer Center (2) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Haisco Pharmaceutical Group (1) Hangzhou SynRx Therapeutics Biomedical Technology (1) Merck & Co. (MSD) (1) Nerviano Medical Sciences (1) Abramson Cancer Center at Penn Medicine (1) Tianjin Medical University Cancer Institute and Hospital (1) National Cancer Institute (NCI) (1) Pfizer (1) Johnson & Johnson (Janssen) (1) Tongji Hospital (1) VA Office of Research and Development (1) Jun Guo (1) Jiangsu Hansoh Pharmaceutical (1) Ruijin Hospital (1) Chia Tai Tianqing Pharmaceutical Group (1)

Related targets

PARP2 (37) PARP3 (9) NAD1 (1) NAMPT (1) TNKS2 (1) TNKS (1) CHRNB2 (1) CHRNA4 (1) Tubulin (1) OPRM1 (1) CD274 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.